甲基受体2型激活减轻炎症性关节炎中心脏和肺部损伤
Andreas Margraf1, Jianmin Chen1, Marilena Christoforou1
1William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
用一种特定的激动剂准甲基受体2型 (FPR2) 可以治疗炎症性关节炎中的心脏和肺功能障碍. 这种方法减少了免疫细胞的透,为类风湿性关节炎并发症提供了新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
背景情况:
- 类风湿性关节炎 (RA) 与严重的心脏和肺部并发症有关,目前的治疗方法无法有效治疗这些并发症.
- 心脏扩张功能障碍和肺部适应性降低是RA患者常见的并发症.
- 在关节炎小鼠模型中,食类同类氨酸会加剧这些情况.
研究的目的:
- 确定甲基受体2型 (FPR2) 作为RA相关心脏和肺功能障碍的治疗标.
- 评估选择性FPR2激动剂在缓解这些并发症方面的疗效.
主要方法:
- 关节炎小鼠具有高水平的同类氨酸被用小分子FPR2激动剂 (BMS986235) 治疗.
- 通过心声回声学评估心脏透静功能.
- 测量了肺部的适应性,组织分析检查了免疫细胞透 (中性粒细胞,单细胞,巨细胞) 和纤维细胞激活.
主要成果:
- 在患有关节炎的小鼠中,FPR2激动剂治疗预防了心脏扩张功能障碍,并恢复了肺部顺应性.
- 治疗效应与受影响组织中中性粒细胞透率的减少有关.
- 观察到心脏中纤维细胞激活的调节和肺中的单细胞/巨细胞数量的减少.
- 双倍的FPR1/2激动剂没有改善肺部的顺应性,并加剧了炎症.
结论:
- 选择性激活FPR2是一种有前途的治疗策略,用于治疗炎症性关节炎中的心脏和肺功能障碍.
- 准FPR2可能会减轻与类风湿性关节炎相关的关键并发症.
- 在这种情况下,FPR1激活可能会对肺炎和纤维化产生有害影响.
更多相关视频
11:03A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
Published on: October 30, 2019
06:48The MUB40 Peptide for Use in Detecting Neutrophil-Mediated Inflammation Events
Published on: January 7, 2019
相关概念视频
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
